Arbutus biopharma Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Arbutus biopharma Contact Number

Contact Arbutus Biopharma

8 hours ago Arbutusbio.com Show details

604.419.3200

Telephone: 604.419.3200. [email protected] Communication concerning transfer requirements, lost share certificates, change of address and other similar inquiries should be addressed to the Transfer Agent and Registrar: AST Trust Company (Canada) Suite …

Category: Contact SupportShow more

Contact Us Arbutus Biopharma Corporation

2 hours ago Investor.arbutusbio.com Show details

The Investor Relations website contains information about Arbutus Biopharma Corporation's business for stockholders, potential investors, and financial analysts.

Category: Contact SupportShow more

Arbutus Biopharma Corporation Profile SEDAR

3 hours ago Sedar.com Show details

Arbutus Biopharma Corporation: Mailing Address: 701 Veterans Circle Warminster, Pennsylvania 18974: Head Office Address: 701 Veterans Circle Warminster, Pennsylvania 18974: Contact Name: Dave Kille: Principal Regulator: British Columbia: Business e-mail address: [email protected]: Short Form Prospectus Issuer: Yes: Telephone Number: 267 469

Contact Name: Dave Kille
Principal Regulator: British Columbia

Category: Contact NumberShow more

Arbutus Biopharma Crunchbase Company Profile & …

7 hours ago Crunchbase.com Show details

(604) 419-3200

Phone Number (604) 419-3200. Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). They believe that Arbutus' comprehensive HBV pipeline of

Founded: Jul 01, 2007
Location: Burnaby, British Columbia

Category: Contact NumberShow more

Board of Directors Arbutus Biopharma Corporation

8 hours ago Investor.arbutusbio.com Show details

Independent Director. Dr. Venker has served on Arbutus’s board of directors since February 2020. Dr. Venker has served as Chief Operating Officer of Roivant Sciences, Inc. (RSI) since November 2018. From October 2017 to October 2018, he served as Chief of Staff to RSI’s Chief Executive Officer, and from 2014 to 2015 as an Analyst at RSI.

Category: Contact NumberShow more

Assembly Biosciences and Arbutus Biopharma Initiate …

7 hours ago Investor.assemblybio.com Show details

(415) 521-3828

Investor Contact Assembly Bio Lauren Glaser Senior Vice President, Investor Relations and Corporate Affairs (415) 521-3828 [email protected] Media Contact Sam Brown Inc. Audra Friis (917) 519-9577 [email protected] Arbutus Contacts Investors and Media: William H. Collier President and CEO Phone: 267-469-0914 [email protected] Pam

Category: Contact NumberShow more

ARBUTUS BIOPHARMA CORPORATION FORM 10Q …

1 hours ago Investor.arbutusbio.com Show details

Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 701 Veterans Circle, Warminster, PA 18974 (Address of Principal Executive Offices and Zip Code)

Category: Contact NumberShow more

OnCore Biopharma Crunchbase Company Profile & …

6 hours ago Crunchbase.com Show details

(215) 489-4928

Contact Email [email protected]oncorebiopharma.com Phone Number (215) 489-4928 OnCore Biopharma, Inc. is a privately held biotechnology company focused on the research, development, and commercialization of therapies for the treatment of chronic hepatitis B virus (HBV) infection.

Category: Contact NumberShow more

Arbutus Biopharma Corp (Form: SC 13D/A, Received: 10/03

8 hours ago Content.edgar-online.com Show details

The undersigned (the Subscriber ) hereby irrevocably subscribes for and agrees to purchase from Arbutus Biopharma Corporation (the Company ) that number of preferred shares in the capital of the Company (the Preferred Shares ) set out below for the aggregate subscription amount set out below, representing a subscription price per Preferred

Category: Contact NumberShow more

$ABUS: JUST IN – New forecast is out now for Arbutus

5 hours ago Wallstreetfacts.com Show details

The 52-week high for Arbutus Biopharma Corp is $5.87 and the low is $2.35. We will be moving onto the number of outstanding shares. One is that you can use shares outstanding to calculate the market capitalization, the total value, of a corporation.

Category: Contact NumberShow more

Who owns Arbutus Biopharma? Top stakeholders of ABUS

3 hours ago Stockzoa.com Show details

Dec 2020. 901.00. $3.0k. Positions data for Arbutus Biopharma. ×. This data is downloadable for data subscribers .*. To download the data without a subscription, you can purchase 90-day access to Arbutus Biopharma position data for $18.00 USD (one time). Email address.

Category: Contact NumberShow more

Arbutus Biopharma Corp (Form: 8K, Received: 05/18/2020 17

6 hours ago Content.edgar-online.com Show details

Warminster, PA - May 18, 2020 - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection …

Category: Contact NumberShow more

Arbutus Biopharma Number of Employees 20082021 ABUS

4 hours ago Macrotrends.net Show details

Arbutus Biopharma number of employees from 2008 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

Category: Contact NumberShow more

Arbutus to Report Third Quarter 2020 Arbutus Biopharma

Just Now Investor.arbutusbio.com Show details

WARMINSTER, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its third quarter 2020 …

Category: Contact NumberShow more

$ABUS: JUST IN – New data and price prediction is out now

2 hours ago Wallstreetfacts.com Show details

The 52-week high for Arbutus Biopharma Corp is $5.87 and the low is $2.43. We will be moving onto the number of outstanding shares. One is that you can use shares outstanding to calculate the market capitalization, the total value, of a corporation.

Category: Contact NumberShow more

How to buy Arbutus Biopharma Corporation stock 30 Sept

3 hours ago Finder.com Show details

Over the last 12 months, Arbutus Biopharma Corporation's stocks have ranged in value from as little as $2.31 up to $5.14. A popular way to gauge a stock's volatility is its "beta". Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma Corporation's is 2.872.

Category: Contact NumberShow more

Mark J. Murray Crunchbase Person Profile

7 hours ago Crunchbase.com Show details

Number of Past Jobs 1 Mark J. Murray is the CEO at Protiva Biotherapeutics . Additionally, Mark J. Murray has had 1 past job as the President & Chief Executive Officer at Arbutus Biopharma .

Category: Contact NumberShow more

Homepage Abdera Therapeutics

1 hours ago Abderatherapeutics.com Show details

Dr. Abrams is the former CEO of Inimex Pharmaceuticals, Chief Innovation Officer at CDRD Ventures, and Managing Director of Arbutus Biopharma. He was the founding CEO of AnorMED which developed the FDA-approved stem cell mobilizing drug, Mozobil and was acquired by Genzyme for over $500M.

Category: Home PhoneShow more

Arbutus to Report Second Quarter 2021 Financial Results

1 hours ago Investor.arbutusbio.com Show details

WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it …

Category: Contact NumberShow more

OpenLabel Study of AB729, Nucleos(t)Ide Analogue and

1 hours ago Clinicaltrials.gov Show details

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04980482

Category: Contact NumberShow more

Moderna Asks Fed. Circ. To Undo DrugDelivery Patent

7 hours ago Law360.com Show details

The case is ModernaTX Inc. et al. v. Arbutus Biopharma Corp., case number 20-2329, in the U.S. Court of Appeals for the Federal Circuit. --Additional reporting by Dave Simpson. Editing by Steven

Category: Contact NumberShow more

Moderna's Appeal Based On 'Imagined' Error, Fed. Circ

4 hours ago Law360.com Show details

The case is ModernaTX Inc. et al. v. Arbutus Biopharma Corp., case number 20-2329, in the U.S. Court of Appeals for the Federal Circuit. --Additional reporting by Dave Simpson. Editing by Daniel King.

Category: Contact NumberShow more

Arbutus to Report Fourth Quarter and Year End 2020

9 hours ago Finance.yahoo.com Show details

(855) 859-2056

Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 4084504. Arbutus Biopharma Corporation is a …

Category: Contact NumberShow more

Arbutus Biopharma (ABUS) Q2 2021 Earnings Call Transcript

9 hours ago Fool.com Show details

Welcome to the Arbutus Biopharma Corporation 2021 second-quarter financial results and corporate update conference call. At this time, all participants are in a listen-only mode.

Category: Contact NumberShow more

Arbutus Biopharma Corp (Form: 8K, Received: 03/26/2020 17

6 hours ago Content.edgar-online.com Show details

604-419-3200

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B (HBV) infection. Contact Information . Investors and Media. William H. Collier. President and CEO . Phone: 604-419-3200 A number of

Category: Contact NumberShow more

Will Moderna Buy ABUS Stock? Insider Financial

4 hours ago Insiderfinancial.com Show details

An administrative court run by the U.S. Patent and Trademark Office has rejected arguments by Moderna that an ABUS Stock patent known as the ‘069 patent should be revoked. The news wiped over $2 billion off the market cap of Moderna and sent ABUS stock flying. ABUS stock closed the day up 119%, yet its […]

Category: Contact NumberShow more

Arbutus to Report Second Quarter 2021 Financial Results

Just Now Finance.yahoo.com Show details

WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and

1. Author: Arbutus Biopharma Corporation

Category: Contact NumberShow more

Arbutus Receives Authorization to Proceed with an

Just Now Finance.yahoo.com Show details

A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and

1. Author: Arbutus Biopharma Corporation

Category: Contact NumberShow more

Arbutus to Report Fourth Quarter and Year End 2020

2 hours ago Ca.finance.yahoo.com Show details

WARMINSTER, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its fourth quarter and …

Category: Contact NumberShow more

Vivek Ramaswamy Founder & Executive Chairman @ Roivant

9 hours ago Crunchbase.com Show details

Vivek Ramaswamy is Founder and Chief Executive Officer of Roivant Sciences. Roivant advances the development and delivery of important medicines in disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal needs. Roivant also builds technology-focused subsidiaries focused on improving the.

Category: Contact NumberShow more

Arbutus to Report First Quarter 2021 Financial Results and

9 hours ago Finance.yahoo.com Show details

WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with

1. Author: Arbutus Biopharma Corporation

Category: Contact NumberShow more

What Do Analysts Think Of Arbutus Biopharma Corporation

9 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 96.87 million. ABUS does have institutional investors; and they hold 31.70% of the stock. Arbutus Biopharma Corporation – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Category: Contact NumberShow more

Should You Sell Arbutus Biopharma Corp (ABUS) Stock

Just Now Investorsobserver.com Show details

Arbutus Biopharma Corp has a Long-Term Technical rank of 83. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 17% of the market scoring higher. In the Biotechnology industry which is number 134 by this metric, ABUS ranks better than 92% of stocks. Important Dates for Investors in ABUS:

Category: Contact NumberShow more

Arbutus Biopharma Corp (ABUS) Stock Price & News Google

8 hours ago Google.com Show details

Get the latest Arbutus Biopharma Corp (ABUS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Category: Contact NumberShow more

Arbutus Biopharma Corporation (ABUS): The long term

Just Now Baxterreport.com Show details

The total number of common shares currently owned by the public is 96.87 million. ABUS does have institutional investors; and they hold 29.60% of the stock. Arbutus Biopharma Corporation – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Category: Contact NumberShow more

Is ABUS A Good Stock To Buy Now? Yahoo

9 hours ago Finance.yahoo.com Show details

The number of bullish hedge fund positions inched up by 1 in recent months. Arbutus Biopharma Corp (NASDAQ:ABUS) was in 9 hedge funds' portfolios at …

Category: Contact NumberShow more

10 Top Penny Stocks To Watch This Week With Potential

6 hours ago Infomagzine.com Show details

ASLAN Pharmaceuticals. Another one of many “Q3 penny stocks to watch” is ASLAN Pharmaceuticals. The firm focuses on remedies for immune ailments. It’s at present evaluating a number of therapy candidates. Its ASLAN004 targets atopic dermatitis, and its ASLAN003 focuses on autoimmune illness. What To Watch With ASLN Stock This Week

Category: Contact NumberShow more

Oral Argument for Moderna TX, Inc. v. Arbutus Biopharma

9 hours ago Courtlistener.com Show details

Support FLP . CourtListener is a project of Free Law Project, a federally-recognized 501(c)(3) non-profit.We rely on donations for our financial security. Please support our work with a donation. Donate Now

Category: Contact NumberShow more

Arbutus Stock Price ABUS Macroaxis

7 hours ago Macroaxis.com Show details

Arbutus Biopharma is selling at 4.16 as of the 14th of October 2021; that is -1.65 percent down since the beginning of the trading day. The stock's lowest day price was 4.06. Get the latest Arbutus Biopharma detailed stock quotes, stock trade data, stock price info, and performance analysis, including Arbutus Stock investment advice, charts, stats and more.

Category: Contact NumberShow more

SEC FORM 4/A

6 hours ago Sec.gov Show details

The reporting person undertakes to provide to Arbutus Biopharma Corp., any security holder of Arbutus Biopharma Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in …

Category: Contact NumberShow more

10 High Penny Shares To Watch This Week With Potential

2 hours ago Epicmerchantsvcs.com Show details

Arbutus Biopharma Company. Shares of Arbutus have been crimson sizzling over the previous few months. Starting in August, ABUS inventory began its climb, benefiting from extra sturdy gross sales leads to the second quarter along with an upbeat outlook from administration regarding Arbutus’ remedy pipeline.

Category: Contact NumberShow more

Arbutus Biopharma Corporation (NASDAQ: ABUS) Gains 15.49%

Just Now Marketingsentinel.com Show details

Arbutus Biopharma Corporation (NASDAQ:ABUS)’s traded shares stood at 10.11 million during the last session, with the company’s beta value hitting 2.68. At the close of trading, the stock’s price was $4.10, to imply an increase of 2.50% or $0.1 in intraday trading. The ABUS share’s 52-week hi

Category: Contact NumberShow more

ARBUTUS BIOPHARMA CORPORATION : Shareholders Board …

6 hours ago Marketscreener.com Show details

Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection.

Category: Contact NumberShow more

Moderna Faces Skeptical Fed. Circ. On Threat To COVID Shot

6 hours ago Law360.com Show details

The cases are ModernaTX Inc. v. Arbutus Biopharma Corp., case numbers 20-1184 and 20-2329, in the U.S. Court of Appeals for the Federal Circuit. --Additional reporting by Tiffany Hu and Dave

Category: Contact NumberShow more

$ABUS: Investors will love the forecast for Arbutus

6 hours ago Wallstreetfacts.com Show details

The 52-week high for Arbutus Biopharma Corp is $5.87 and the low is $2.43. We will be moving onto the number of outstanding shares. One is that you can use shares outstanding to calculate the market capitalization, the total value, of a corporation.

Category: Contact NumberShow more

Arbutus Biopharma : Clinical Overview of AB729, a potent

9 hours ago Marketscreener.com Show details

Arbutus Biopharma Corp. published this content on 14 October 2021 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 14 October 2021 15:31:07 UTC .

Category: Contact NumberShow more

Arbutus Biopharma Corporation (NASDAQ: ABUS): Hidden Gems

6 hours ago Stocksregister.com Show details

The number of analysts that have assigned ABUS a recommendation rating is 5. Out of them, 2 rate it a Hold, while 3 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Arbutus Biopharma Corporation (ABUS) as Underweight, while 0 advise Sell.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is arbutus biopharma?

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection.

How to contact arbutus biopharma for lost share certificates?

Please direct any employment related inquiries to Human Resources. Telephone: 267.469.0914 Fax: 267.282.0411 Telephone: 604.419.3200 Communication concerning transfer requirements, lost share certificates, change of address and other similar inquiries should be addressed to the Transfer Agent and Registrar:

Where are arbutus common shares listed on nasdaq?

Communication concerning transfer requirements, lost share certificates, change of address and other similar inquiries should be addressed to the Transfer Agent and Registrar: Arbutus’ common shares are listed for trading on NASDAQ under the symbol ABUS.

Is it smart for moderna to buy arbutus?

As a result, the smart and only move for Moderna is to purchase Arbutus Biopharma, which has backed Moderna into a corner and there’s no other move the company can make. The stakes for Moderna are too high – in the tens of billions of dollars to hundreds of billions of dollars potentially.

Brand New Updated

Popular Brands

Amazon
Abbvie
Aia
Asml
Amgen
Att
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes